Vivek Anand, MD
Psychiatry · Greenville, NCNPI 1639308901
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $403 of the $478 with a category attached, or 84.3%. 8 manufacturers reported payments, led by Sunovion Pharmaceuticals Inc. at 35.0% of the total. Reporting peaked in 2019 at $180 and has fallen 74.5% since, to $46 in 2025.
Across 16 payments — averaging $29.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$167
- Otsuka America Pharmaceutical, Inc.$113
- Alkermes, Inc.$61
- Indivior Inc.$46
- Boston Scientific$34
- Corium, LLC$28
- plus $29 from 2 others
Across 2 payments — averaging $12,500 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$25K
What the payments were for
- Food & beverage$40384%
- Education$7516%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 5 | $167 |
| Otsuka America Pharmaceutical, Inc. | 1 | $113 |
| Alkermes, Inc. | 2 | $61 |
| Indivior Inc. | 3 | $46 |
| Boston Scientific | 1 | $34 |
| Corium, LLC | 2 | $28 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$478 in reported general payments places this provider in the 60th percentile of 1,108 psychiatry providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 13 | $4,110 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 19 | $992 |
| Bupropion XlBupropion Hcl | 42 | $684 |
| Buspirone Hcl | 77 | $658 |
| Aripiprazole | 31 | $529 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 30 | $443 |
| Gabapentin | 41 | $356 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 13 | $340 |
| Quetiapine Fumarate | 17 | $285 |
| Donepezil Hcl | 37 | $283 |
| Propranolol Hcl | 16 | $256 |
| Memantine Hcl | 24 | $248 |
| Fluoxetine Hcl | 31 | $171 |
| Hydroxyzine Hcl | 23 | $134 |
| Trazodone Hcl | 33 | $126 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Greenville
- Kathy MayoGreenville$14K
- Craig ChepkeHuntersville$4.1M
- Mark ReynoldsDurham$3.2M
- James BarkerHickory$2.1M
- Brian FarahWinston Salem$605K
- Krishna TalluriMorrisville$591K
- Ramesh GihwalaGastonia$545K
- Keshavpal ReddyGreensboro$480K
- Robert MilletRaleigh$476K
- Steven SzaboDurham$360K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.